A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.
Using targeted antibodies in the brain, researchers from the University of Pennsylvania have developed a possible treatment for Parkinson's that intercepts disease-causing proteins accumulating in the neurons. In a proof-of-concept study, the team demonstrated that the antibodies prevented pathology and also reversed the effects of the disease in some cases.
President Obama's Brain Initiative awarded millions to University of California researchers to develop mini brain implants that treat Parkinson's disease and epilepsy.
Researchers at Rice University in Texas have developed a new kind of drug delivery particle: a "tunable" virus that releases a treatment only in the presence of not one but two different enzymes that show elevated levels at the site of a tumor.
Civitas Therapeutics announced that its inhaled formulation of levodopa for the treatment of "off episodes" associated with Parkinson's disease met its primary clinical endpoint in a Phase II trial.
Cynapsus Therapeutics' sublingually delivered reformulation of the drug used to treat advanced Parkinson's disease cleared an initial clinical hurdle, the company said April 24.
Boston Scientific is ramping up neuromodulation efforts with a new clinical trial of its implantable deep brain stimulation device for patients with Parkinson's disease.
After a manufacturing problem irked the FDA and scared off partner GlaxoSmithKline, Impax Laboratories is resubmitting its investigational drug for Parkinson's disease, hoping it can clear an agency inspection and finally get its treatment on the market.
A new patch-like device designed by engineers at the University of Texas at Austin boasts a number of functions, including drug delivery for patients with movement disorders such as epilepsy or Parkinson's disease.
Israeli subcutaneous delivery company NeuroDerm is forging ahead with its Parkinson's patch, enrolling patients in its second Phase II clinical trial of its patch pump designed to treat the disease with steady concentrations of the tried-and-true drug levodopa.